Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
Rhea-AI Summary
Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in suprachoroidal space (SCS®) therapies for eye conditions, has announced its schedule for reporting second quarter 2024 financial results. The company will release its Q2 2024 financials on Monday, August 12, 2024, after the financial markets close. Notably, Clearside has opted not to hold a Q2 2024 conference call. Instead, they recently hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on July 24, 2024, with a replay available on their website. The company plans to resume quarterly earnings conference calls starting with the third quarter 2024 financial results.
Positive
- Timely reporting of Q2 2024 financial results scheduled
- Proactive investor communication through Key Opinion Leader Webinar
- Plans to resume regular quarterly earnings calls from Q3 2024
Negative
- None.
News Market Reaction – CLSD
In the trading session that priced this news, CLSD declined 0.88%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALPHARETTA, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its second quarter 2024 financial results will be reported on Monday, August 12, 2024, after the close of the financial markets.
In lieu of a second quarter 2024 conference call, the Company hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on Wednesday, July 24, 2024. The replay of this event is available on the Clearside website under the Investors section: Events and Presentations. Quarterly earnings conference calls are expected to resume with the third quarter 2024 financial results.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com and follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
